Interferon alpha-2a biosimilar - Biogenomics

Drug Profile

Interferon alpha-2a biosimilar - Biogenomics

Alternative Names: Interferon alfa-2a biosimilar - Biogenomics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogenomics
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alfa 2a stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Chronic myeloid leukaemia; Hairy cell leukaemia; Hepatitis C; Kaposi's sarcoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Chronic-myeloid-leukaemia in India (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Hairy-cell-leukaemia in India (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Hepatitis-C in India (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top